Red Cat Holdings heads into its fiscal Q4 earnings report tomorrow — June 18 — with short sellers unmoved, the borrow market tight but not stressed, and options traders leaning slightly more bullish than usual.
The short position tells a stubborn story. Short interest has edged up a further 4% on the week to 23.8% of the free float — essentially unchanged from the 23.4% flagged in Monday's earnings preview note, and still one of the heaviest short positions in defense-tech small caps. Bears have not blinked ahead of the print. The ORTEX short score holds at 68.3, a persistently elevated reading that has barely moved all month. Borrow availability has loosened slightly — up to 34% from around 27% earlier in the week — but remains tight in absolute terms, meaning there are roughly one-third as many shares available to borrow as there are already out on loan. The cost to borrow has nudged up 22% on the week to just over 1%, but that is still a fraction of the near-4% levels seen in early May when availability briefly hit zero. Shorts face no meaningful financial pressure to cover before the report.
Options positioning offers a mild contrast. The put/call ratio has eased to 0.45, slightly below its 20-day average of 0.47 and near the lower end of recent ranges. That is a marginally call-skewed reading — suggesting options traders are not rushing to buy downside protection ahead of earnings. It is not a strong conviction signal either way, but it does sit at odds with the elevated short position.
The Street remains firmly bullish, even as the stock trades at $10.90 — roughly half the consensus price target of $22. Roth Capital initiated coverage with a Buy and a $25 target as recently as June 1, and HC Wainwright followed days earlier with a $20 target initiation. All five analysts covering the stock carry Buy ratings. The bull case rests on RCAT's SRR2 drone program, defense sector tailwinds as the U.S. Army rebuilds domestic drone capability, and revenue growth that topped 341% year-on-year. Bears are not on the analyst panel, but they are very much in the market — their concern centers on execution risk, unpredictable defense budgets, and the company's pre-profitability profile. Valuation multiples reflect the loss-making stage: P/E and EV/EBITDA are both deeply negative, and the earnings yield factor ranks in the bottom quartile. The one bright spot on fundamentals is the EPS surprise score, which ranks in the 99th percentile of the universe — RCAT has consistently beaten estimates when it has reported.
One insider move is worth noting. Director Paul Funk sold 165,028 shares at $11.50 on June 11, a transaction valued at roughly $1.9 million. That is not a trivial disposal, and it came just days before the earnings release. Against that, the 90-day net insider position is marginally positive in share terms — but the Funk sale is the most significant single transaction in the recent record and arrived close enough to the print to be worth flagging. Institutional ownership has been building: BlackRock added 2.78 million shares as of May 31, and T. Rowe Price entered with 2.26 million shares by end of Q1. Passive and active money is accumulating even as the short position holds firm.
Among peers, the sector had a rough week. RDW fell 14% on the week, AIRO dropped 8.5%, and SPAI shed 7.9%. RCAT's own 5.2% weekly decline and Tuesday's 8.9% single-day drop put it broadly in line with the group's weakness rather than isolated. KRMN was the outlier, gaining nearly 7% on the week, suggesting sector-level pain rather than a stock-specific story drove Monday's selloff.
The June 18 earnings print is now the single variable that matters — specifically whether RCAT can show a path toward profitability alongside revenue growth, and how management frames the SRR2 program ramp into full-rate production.
See the live data behind this article on ORTEX.
Open RCAT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
